Clinical proteomics-driven precision medicine for targeted cancer therapy: Current overview and future perspectives

Expert Review of Proteomics

Volumn 13, Issue 4, 2016, Pages 367-381

  Zhou, Li ^a,b   Wang, Kui ^a   Li, Qifu ^b   Nice, Edouard C ^a,c   Zhang, Haiyuan ^b   Huang, Canhua ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

^c MONASH UNIVERSITY   (Australia)

Author keywords

cancer therapy; Clinical proteomics; drug target identification; mass spectrometry; precision medicine

Indexed keywords

TUMOR MARKER;

BIOINFORMATICS; BLOOD; CANCER DIAGNOSIS; CANCER TISSUE; DRUG RESPONSE; DRUG TARGETING; EARLY DIAGNOSIS; FECES; HUMAN; INTERSTITIAL FLUID; ISOBARIC TAG FOR THE RELATIVE AND ABSOLUTE QUANTITATION; ISOTOPE LABELING; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; PLEURA EFFUSION; PROTEIN ANALYSIS; PROTEOMICS; QUALITATIVE ANALYSIS; REVIEW; SALIVA; STABLE ISOTOPE LABELING BY AMINO ACID IN CELL CULTURE; TANDEM MASS SPECTROMETRY; TUMOR MICROENVIRONMENT; URINE; ANIMAL; METABOLISM; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; PROTEOMICS;

EID: 84961211571     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2016.1159959     Document Type: Review

References (171)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61 (2): 69-90
2. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer?. Nat Rev Cancer. 2012; 12 (5): 323-334
3. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002; 1 (9): 683-695
4. Apweiler R, Aslanidis C, Deufel T, et al. Approaching clinical proteomics: Current state and future fields of application in fluid proteomics. Clin Chem Lab Med CCLM/FESCC. 2009; 47 (6): 724-744
5. Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. PROTEOMICS-Clin Appl. 2007; 1 (2): 148-156
6. Mendelsohn J. Personalizing oncology: Perspectives and prospects. J Clin Oncol Off J Am Soc Clin Oncol. 2013; 31 (15): 1904-1911
7. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med. 2015; 372 (23): 2229-2234
8. National Research Council. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease [. Internet ]. Washington, DC: National Academies Press; 2011. Available from: (http://www.nap.edu/catalog/13284/toward-precision-medicine-building-a-knowledge-network-for-biomedical-research).)
9. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372 (9): 793-795
10. Shrager J, Tenenbaum JM. Rapid learning for precision oncology. Nat Rev Clin Oncol. 2014; 11 (2): 109-118
11. Blau CA, Liakopoulou E. Can we deconstruct cancer, one patient at a time?. Trends Genet TIG. 2013; 29 (1): 6-10
12. Wisniewski JR, Dus K, Mann M. Proteomic workflow for analysis of archival formalin-fixed and paraffin-embedded clinical samples to a depth of 10 000 proteins. Proteomics Clin Appl. 2013; 7 (3-4): 225-233
13. Bauer JA, Chakravarthy AB, Rosenbluth JM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010; 16 (2): 681-690
14. Meding S, Balluff B, Elsner M, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol. 2012; 228 (4): 459-470
15. Wang W, Jia HL, Huang JM, et al. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014; 110 (7): 1748-1758
16. Gamez-Pozo A, Sanchez-Navarro I, Nistal M, et al. MALDI profiling of human lung cancer subtypes. PLoS One. 2009; 4 (11): E7731
17. Kikuta K, Tochigi N, Saito S, et al. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl. 2010; 4 (5): 560-567
18. Tweedle EM, Khattak I, Ang CW, et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut. 2010; 59 (11): 1501-1510
19. Wang LN, Tong SW, Hu HD, et al. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J Cell Biochem. 2012; 113 (12): 3762-3772
20. Heo SH, Lee SJ, Ryoo HM, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics. 2007; 7 (23): 4292-4302
21. Zeng X, Hood BL, Sun M, et al. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res. 2010; 9 (12): 6440-6449
22. Kang SM, Sung HJ, Ahn JM, et al. The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol Biosyst. 2011; 7 (4): 1167-1175
23. Pitteri SJ, Amon LM, Busald Buson T, et al. Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res. 2010; 70 (21): 8598-8606
24. Murakoshi Y, Honda K, Sasazuki S, et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. 2011; 102 (3): 630-638
25. Chen YT, Chen CL, Chen HW, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res. 2010; 9 (11): 5803-5815
26. True LD, Zhang H, Ye M, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Modern Pathol. 2010; 23 (10): 1346-1356
27. Ang CS, Rothacker J, Patsiouras H, et al. Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis. 2011; 32 (15): 1926-1938
28. Ang CS, Nice EC. Targeted in-gel MRM: A hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res. 2010; 9 (9): 4346-4355
29. Xiao H, Zhang L, Zhou H, et al. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteom MCP. 2012; 11 (2): M111 012112
30. Zabron AA, Horneffer-Van Der Sluis VM, Wadsworth CA, et al. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol. 2011; 106 (9): 1711-1717
31. Desiderio C, DAngelo L, Rossetti DV, et al. Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics. 2012; 12 (13): 2158-2166
32. Kosanam H, Makawita S, Judd B, et al. Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics. 2011; 11 (23): 4551-4558
33. Haslene-Hox H, Oveland E, Woie K, et al. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Biochim Biophys Acta. 2013; 1834 (11): 2347-2359
34. Dogan A. Advances in clinical applications of tissue proteomics: Opportunities and challenges. Expert Rev Proteomics. 2014; 11 (5): 531-533
35. Casadonte R, Caprioli RM. Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat Protoc. 2011; 6 (11): 1695-1709
36. Fowler CB, OLeary TJ, Mason JT. Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue. Expert Rev Proteomics. 2013; 10 (4): 389-400
37. Angel PM, Caprioli RM. Matrix-assisted laser desorption ionization imaging mass spectrometry: In situ molecular mapping. Biochemistry. 2013; 52 (22): 3818-3828
38. Balluff B, Elsner M, Kowarsch A, et al. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteome Res. 2010; 9 (12): 6317-6322
39. Lindskog C. The potential clinical impact of the tissue-based map of the human proteome. Expert Rev Proteomics. 2015; 12 (3): 213-215
40. Xu BJ. Combining laser capture microdissection and proteomics: Methodologies and clinical applications. Proteomics Clin Appl. 2010; 4 (2): 116-123
41. Imielinski M, Cha S, Rejtar T, et al. Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteom MCP. 2012; 11 (6): M111 014910
42. Datta S, Malhotra L, Dickerson R, et al. Laser capture microdissection: Big data from small samples. Histol Histopathol. 2015; 30 (11): 1255-1269
43. Indovina P, Marcelli E, Pentimalli F, et al. Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery. Mass Spectrom Rev. 2013; 32 (2): 129-142
44. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011; 8 (3): 142-150
45. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005; 5 (13): 3226-3245
46. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006; 116 (1): 271-284
47. Liotta LA, Petricoin EF. Mass spectrometry-based protein biomarker discovery: Solving the remaining challenges to reach the promise of clinical benefit. Clin Chem. 2010; 56 (10): 1641-1642
48. Gold L, Walker JJ, Wilcox SK, et al. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol. 2012; 29 (5): 543-549
49. Taguchi A, Hanash SM. Unleashing the power of proteomics to develop blood-based cancer markers. Clin Chem. 2013; 59 (1): 119-126
50. Gewinner C, Hart G, Zachara N, et al. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem. 2004; 279 (5): 3563-3572
51. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4 (6): 477-488
52. Kyselova Z, Mechref Y, Kang P, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008; 54 (7): 1166-1175
53. Narayanasamy A, Ahn JM, Sung HJ, et al. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics. 2011; 74 (12): 2948-2958
54. Tsai HY, Boonyapranai K, Sriyam S, et al. Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics. 2011; 11 (11): 2162-2170
55. Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI, et al. Can the acute-phase reactant proteins be used as cancer biomarkers?. Int J Biol Markers. 2010; 25 (1): 1-11
56. Sung HJ, Ahn JM, Yoon YH, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011; 10 (3): 1383-1395
57. Sanchez-Carbayo M. Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2010; 31 (2): 103-112.
58. Reumer A, Maes E, Mertens I, et al. Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: Truth or dare?. Expert Rev Proteomics. 2014; 11 (4): 449-463
59. Ray S, Reddy PJ, Jain R, et al. Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead. Proteomics. 2011; 11 (11): 2139-2161
60. Tan HT, Lee YH, Chung MC. Cancer proteomics. Mass Spectrom Rev. 2012; 31 (5): 583-605
61. Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics. 2005; 5 (13): 3262-3277
62. Omenn GS. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis Markers. 2004; 20 (3): 131-134
63. Ray S, Mehta G, Srivastava S. Label-free detection techniques for protein microarrays: Prospects, merits and challenges. Proteomics. 2010; 10 (4): 731-748
64. Ladd J, Taylor AD, Piliarik M, et al. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem. 2009; 393 (4): 1157-1163
65. Lee SJ, Youn BS, Park JW, et al. ssDNA aptamer-based surface plasmon resonance biosensor for the detection of retinol binding protein 4 for the early diagnosis of type 2 diabetes. Anal Chem. 2008; 80 (8): 2867-2873
66. Lausted C, Hu Z, Hood L. Quantitative serum proteomics from surface plasmon resonance imaging. Mol Cell Proteom MCP. 2008; 7 (12): 2646-2474
67. Okuno J, Maehashi K, Kerman K, et al. Label-free immunosensor for prostate-specific antigen based on single-walled carbon nanotube array-modified microelectrodes. Biosens Bioelectron. 2007; 22 (9-10): 2377-2381
68. Zheng G, Patolsky F, Cui Y, et al. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol. 2005; 23 (10): 1294-1301
69. Srivastava S, LaBaer J. Nanotubes light up protein arrays. Nat Biotechnol. 2008; 26 (11): 1244-1246
70. Zhu H, Dale PS, Caldwell CW, et al. Rapid and label-free detection of breast cancer biomarker CA15-3 in clinical human serum samples with optofluidic ring resonator sensors. Anal Chem. 2009; 81 (24): 9858-9865
71. Washburn AL, Gunn LC, Bailey RC. Label-free quantitation of a cancer biomarker in complex media using silicon photonic microring resonators. Anal Chem. 2009; 81 (22): 9499-9506
72. Von Muhlen MG, Brault ND, Knudsen SM, et al. Label-free biomarker sensing in undiluted serum with suspended microchannel resonators. Anal Chem. 2010; 82 (5): 1905-1910
73. Ang CS, Rothacker J, Patsiouras H, et al. Murine fecal proteomics: A model system for the detection of potential biomarkers for colorectal cancer. J Chromatogr A. 2010; 1217 (19): 3330-3340
74. Hu S, Loo JA, Wong DT. Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics. 2007; 4 (4): 531-538
75. Mannello F, Ligi D. Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer. 2013; 13: 344
76. Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, et al. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics. 2010; 73 (8): 1511-1522
77. Nilsson T, Mann M, Aebersold R, et al. Mass spectrometry in high-throughput proteomics: Ready for the big time. Nat Methods. 2010; 7 (9): 681-685
78. Wu FX, Ressom H, Dunn MJ. Focus on bioinformatics in proteomics. Proteomics. 2013; 13 (2): 219-220
79. Grebe SK, Singh RJ. LC-MS/MS in the Clinical Laboratory-Where to From Here?. Clin Biochem Rev Aust Assoc Clin Biochemists. 2011; 32 (1): 5-31
80. Chen G, Pramanik BN. Application of LC/MS to proteomics studies: Current status and future prospects. Drug Discov Today. 2009; 14 (9-10): 465-471
81. Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell. 2009; 138 (4): 795-806
82. Hoofnagle AN, Becker JO, Oda MN, et al. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem. 2012; 58 (4): 777-781
83. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2013; 10 (1): 28-34
84. Huttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012; 4 (142): 142ra194
85. Whiteaker JR, Lin C, Kennedy J, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol. 2011; 29 (7): 625-634
86. Pan S, Chen R, Brand RE, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: A pancreatic cancer biomarker case study. J Proteome Res. 2012; 11 (3): 1937-1948
87. Percy AJ, Chambers AG, Yang J, et al. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. Proteomics. 2013; 13 (14): 2202-2215
88. Kitteringham NR, Jenkins RE, Lane CS, et al. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877 (13): 1229-1239
89. Selevsek N, Matondo M, Sanchez Carbayo M, et al. Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics. 2011; 11 (6): 1135-1147
90. Keshishian H, Addona T, Burgess M, et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteom MCP. 2007; 6 (12): 2212-2229
91. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009; 27 (7): 633-641
92. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: Workflows, potential, pitfalls and future directions. Nat Methods. 2012; 9 (6): 555-566
93. Fortin T, Salvador A, Charrier JP, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteom MCP. 2009; 8 (5): 1006-1015
94. Peng J, Elias JE, Thoreen CC, et al. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: The yeast proteome. J Proteome Res. 2003; 2 (1): 43-50
95. Dams R, Huestis MA, Lambert WE, et al. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom. 2003; 14 (11): 1290-1294
96. Gros M, Petrović M, Barceló D. Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. Talanta. 2006; 70 (4): 678-690
97. Bogdanov B, Smith RD. Proteomics by FTICR mass spectrometry: Top down and bottom up. Mass Spectrom Rev. 2005; 24 (2): 168-200
98. Zhou L, Li Q, Wang J, et al. Oncoproteomics: Trials and Tribulations. Proteomics Clin Appl. 2015
99. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: Approaches, advances, and applications. Annu Rev Biomed Eng. 2009; 11: 49-79
100. Cramer R, Gobom J, Nordhoff E. High-throughput proteomics using matrix-assisted laser desorption/ionization mass spectrometry. Expert Rev Proteomics. 2005; 2 (3): 407-420
101. Rodrigo MAM, Zitka O, Krizkova S, et al. MALDI-TOF MS as evolving cancer diagnostic tool: A review. J Pharm Biomed Anal. 2014; 95: 245-255
102. Cho YT, Su H, Wu WJ, et al., Biomarker Characterization by MALDI-TOF/MS. Adv Clin Chem. 2015; 69: 209-254
103. Pusch W, Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des. 2005; 11 (20): 2577-2591
104. Castellino S, Groseclose MR, Wagner D. MALDI imaging mass spectrometry: Bridging biology and chemistry in drug development. Bioanalysis. 2011; 3 (21): 2427-2441
105. Cho Y-T, Su H, Huang T-L, et al. Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry for clinical diagnosis. Clin Chim Acta. 2013; 415: 266-275
106. Iwadate Y. Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis. Curr Med Chem. 2008; 15 (23): 2393-2400
107. Roman E, Lunde MLS, Miron T, et al. Analysis of protein expression profile of oral squamous cell carcinoma by MALDI-TOF-MS. Anticancer Res. 2013; 33 (3): 837-845
108. Spengler B. Mass spectrometry imaging of biomolecular information. Anal Chem. 2015; 87 (1): 64-82
109. Gromov P, Moreira JMA, Gromova I. Proteomic analysis of tissue samples in translational breast cancer research. Expert Rev Proteomics. 2014; 11 (3): 285-302
110. Rauser S, Deininger S-O, Suckau D, et al. Approaching MALDI molecular imaging for clinical proteomic research: Current state and fields of application. Expert Rev Proteomics. 2010; 7 (6): 927-941
111. Cazares LH, Troyer DA, Wang B, et al. MALDI tissue imaging: From biomarker discovery to clinical applications. Anal Bioanal Chem. 2011; 401 (1): 17-27
112. Schwamborn K. Imaging mass spectrometry in biomarker discovery and validation. J Proteomics. 2012; 75 (16): 4990-4998
113. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry-looking beyond classical histology. Nat Rev Cancer. 2010; 10 (9): 639-646
114. Meding S, Nitsche U, Balluff B, et al. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res. 2012; 11 (3): 1996-2003
115. Schöne C, Höfler H, Walch A. MALDI imaging mass spectrometry in cancer research: Combining proteomic profiling and histological evaluation. Clin Biochem. 2013; 46 (6): 539-545
116. Balluff B, Schöne C, Höfler H, et al. MALDI imaging mass spectrometry for direct tissue analysis: Technological advancements and recent applications. Histochem Cell Biol. 2011; 136 (3): 227-244
117. Minerva L, Clerens S, Baggerman G, et al. Direct profiling and identification of peptide expression differences in the pancreas of control and ob/ob mice by imaging mass spectrometry. Proteomics. 2008; 8 (18): 3763-3774
118. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999; 17 (10): 994-999
119. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteom MCP. 2004; 3 (12): 1154-1169
120. Geiger T, Wisniewski JR, Cox J, et al. Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat Protoc. 2011; 6 (2): 147-157
121. DeSouza L, Diehl G, Rodrigues MJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2005; 4 (2): 377-386
122. Burkhart JM, Vaudel M, Zahedi RP, et al. iTRAQ protein quantification: A quality-controlled workflow. Proteomics. 2011; 11 (6): 1125-1134
123. Pierce A, Unwin RD, Evans CA, et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics. 2008; 7 (5): 853-863
124. Zieske LR. A perspective on the use of iTRAQ™ reagent technology for protein complex and profiling studies. J Exp Bot. 2006; 57 (7): 1501-1508
125. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006; 7 (12): 952-958
126. Ong S-E, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol. 2005; 1 (5): 252-262
127. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome. PROTEOMICS-Clin Appl. 2013; 7 (5-6): 355-366
128. Bantscheff M, Lemeer S, Savitski MM, et al. Quantitative mass spectrometry in proteomics: Critical review update from 2007 to the present. Anal Bioanal Chem. 2012; 404 (4): 939-965
129. Xie F, Liu T, Qian W-J, et al. Liquid chromatography-mass spectrometry-based quantitative proteomics. J Biol Chem. 2011; 286 (29): 25443-25449
130. Levin Y, Schwarz E, Wang L, et al. Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J Sep Sci. 2007; 30 (14): 2198-2203
131. Acosta-Martin AE, Lane L. Combining bioinformatics and MS-based proteomics: Clinical implications. Expert Rev Proteomics. 2014; 11 (3): 269-284
132. Neilson KA, Ali NA, Muralidharan S, et al. Less label, more free: Approaches in label-free quantitative mass spectrometry. Proteomics. 2011; 11 (4): 535-553
133. Zhang B, VerBerkmoes NC, Langston MA, et al. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res. 2006; 5 (11): 2909-2918
134. Pham TV, Piersma SR, Oudgenoeg G, et al. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn. 2012; 12 (4): 343-359
135. Orchard S. Data standardization and sharing -The work of the HUPO-PSI. Biochim Biophys Acta (BBA)-Proteins Proteom. 2014; 1844 (1): 82-87
136. Turewicz M, Deutsch EW. Spectra, chromatograms, metadata: MzML -The standard data format for mass spectrometer output. In: Data mining in proteomics. Springer; 2011. p. 179-203
137. Walzer M, Qi D, Mayer G, et al. The mzQuantML data standard for mass spectrometry-based quantitative studies in proteomics. Mol Cell Proteomics. 2013; 12 (8): 2332-2340
138. Field HI, Fenyo D, Beavis RC. RADARS, a bioinformatics solution that automates proteome mass spectral analysis, optimises protein identification, and archives data in a relational database. Proteomics. 2002; 2 (1): 36
139. Srinivas PR, Verma M, Zhao Y, et al. Proteomics for cancer biomarker discovery. Clin Chem. 2002; 48 (8): 1160-1169
140. Kim H, Kim K, Yu SJ, et al. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring. PLoS One. 2012;8(5):e63468
141. Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol. 2012; 19 (1): 72-84
142. Liu Y, Guo M. Chemical proteomic strategies for the discovery and development of anticancer drugs. Proteomics. 2014; 14 (4-5): 399-411
143. Sutton CW. The role of targeted chemical proteomics in pharmacology. Br J Pharmacol. 2012; 166 (2): 457-475
144. Yuan K, Lei Y, Huang C. Application of chemistry-based functional proteomics to screening for novel drug targets. Comb Chem High Throughput Screen. 2010; 13 (5): 414-421
145. Wang K, Yang T, Wu Q, et al. Chemistry-based functional proteomics for drug target deconvolution. Expert Rev Proteomics. 2012; 9 (3): 293-310
146. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009; 5 (9): 616-624
147. Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011; 71 (4): 1396-1405
148. Colzani M, Noberini R, Romanenghi M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteom MCP. 2014; 13 (6): 1495-1509
149. Sartippour MR, Seeram NP, Heber D, et al. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol. 2005; 26 (1): 121-127
150. Dal Piaz F, Cotugno R, Lepore L, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013; 82: 14-26
151. Sawyers C. Targeted cancer therapy. Nature. 2004; 432 (7015): 294-297
152. Celis JE, Gromov P, Cabezón T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment A novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics. 2004; 3 (4): 327-344
153. Rauser S, Marquardt C, Balluff B, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010; 9 (4): 1854-1863
154. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med. 2005; 353 (16): 1673-1684
155. Cohen AA, Geva-Zatorsky N, Eden E, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008; 322 (5907): 1511-1516
156. Ortiz PA, Bruno ME, Moore T, et al. Proteomic analysis of propiconazole responses in mouse liver: Comparison of genomic and proteomic profiles. J Proteome Res. 2010; 9 (3): 1268-1278
157. Klein O, Rohwer N, De Molina KF, et al. Application of two-dimensional gel-based mass spectrometry to functionally dissect resistance to targeted cancer therapy. Proteomics Clin Appl. 2013; 7(11-12): 813-824
158. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012; 148 (6): 1293-1307
159. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: The clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr Drug Metab. 2014; 15 (2): 209-217
160. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010; 363 (24): 2339-2350
161. Britton LM, Sova P, Belisle S, et al. A proteomic glimpse into the initial global epigenetic changes during HIV infection. Proteomics. 2014; 14 (19): 2226-2230
162. Marino G, Eckhard U, Overall CM. Protein termini and their modifications revealed by positional proteomics. ACS Chem Biol. 2015; 10 (8): 1754-1764
163. Rogers LD, Overall CM. Proteolytic post-translational modification of proteins: Proteomic tools and methodology. Mol Cell Proteom MCP. 2013; 12 (12): 3532-3542
164. Eckhard U, Marino G, Butler GS, et al. Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie. 2016; 122: 110-118
165. Nishi A, Milner DA Jr., Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016; 16 (1): 11-23
166. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut. 2011; 60 (3): 397-411
167. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Modern Pathol. 2013; 26 (4): 465-484
168. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26 (35): 5713-5720
169. Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015; 26 (7): 959-972
170. Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: Challenges and opportunities. Respirology. 2007; 12 (1): 22-28
171. Pawa N, Wright JM, Arulampalam TH. Mass spectrometry based proteomic profiling for pancreatic cancer. JOP J Pancreas. 2010; 11 (5): 423-426.